US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
Molecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, IA, United States C3 Glomerulopathy (C3G) is a renal disease mediated primarily by dysregulation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback